Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Eluxadoline (Truberzi®) has been rejected for use in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D). The submitting company did not present a sufficiently robust economic analysis to gain acceptance

Metformin hydrochloride (Glucophage SR®) has been rejected for use to reduce the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose and/or increased HbA1C who are:

  • at high risk for developing overt type 2 diabetes mellitus and
  • still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months

The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2018' on Email Share 'SMC Update - January 2018' on Delicious Share 'SMC Update - January 2018' on Digg Share 'SMC Update - January 2018' on Facebook Share 'SMC Update - January 2018' on Google+ Share 'SMC Update - January 2018' on reddit Share 'SMC Update - January 2018' on StumbleUpon Share 'SMC Update - January 2018' on Twitter

atomic-wealth

No Comments to “SMC Update - January 2018”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 4,725 spam comments.

atomic-wealth
fond-illness
summer